|
1
|
Landgren O and Morgan GJ: Biologic frontiers in multiple myeloma: From biomarker identification to clinical practice. Clin Cancer Res. 20:804–813. 2014. View Article : Google Scholar
|
|
2
|
Reisenbuckler C: Multiple myeloma and diagnostic imaging. Radiol Technol. 85:391–413. 2014.PubMed/NCBI
|
|
3
|
Orlowski RZ: Why proteasome inhibitors cannot ERADicate multiple myeloma. Cancer Cell. 24:275–277. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
McCullough KB, Hobbs MA, Abeykoon JP and Kapoor P: Common adverse effects of novel therapies for multiple myeloma (MM) and their management strategies. Curr Hematol Malig Rep. 13:114–124. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Naymagon L and Abdul-Hay M: Novel agents in the treatment of multiple myeloma: A review about the future. J Hematol Oncol. 9:522016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ria R, Reale A and Vacca A: Novel agents and new therapeutic approaches for treatment of multiple myeloma. World J Methodol. 4:73–90. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Varga C, Laubach J, Hideshima T, Chauhan D, Anderson KC and Richardson PG: Novel targeted agents in the treatment of multiple myeloma. Hematol Oncol Clin North Am. 28:903–925. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kelly T, Børset M, Abe E, Gaddy-Kurten D and Sanderson RD: Matrix metalloproteinases in multiple myeloma. Leuk Lymphoma. 37:273–281. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Takimoto M, Ogawa K, Kato Y, Saito T, Suzuki T, Irei M, Shibuya Y, Suzuki Y, Kato M, Inoue Y, et al: Close relation between 14q32/IGH translocations and chromosome 13 abnormalities in multiple myeloma: A high incidence of 11q13/CCND1 and 16q23/MAF. Int J Hematol. 87:260–265. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Largo C, Saéz B, Alvarez S, Suela J, Ferreira B, Blesa D, Prosper F, Calasanz MJ and Cigudosa JC: Multiple myeloma primary cells show a highly rearranged unbalanced genome with amplifications and homozygous deletions irrespective of the presence of immunoglobulin-related chromosome translocations. Haematologica. 92:795–802. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bergsagel PL and Kuehl WM: Chromosome translocations in multiple myeloma. Oncogene. 20:5611–5622. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Issa ME, Takhsha FS, Chirumamilla CS, Perez-Novo C, Vanden Berghe W and Cuendet M: Epigenetic strategies to reverse drug resistance in heterogeneous multiple myeloma. Clin Epigenetics. 9:172017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Liang X, Deng M, Zhang C, Ping F, Wang H, Wang Y, Fan Z, Ren X, Tao X, Wu T, et al: Combined class I histone deacetylase and mTORC1/C2 inhibition suppresses the initiation and recurrence of oral squamous cell carcinomas by repressing SOX2. Cancer Lett. 454:108–119. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Jeon YJ, Ko SM, Cho JH, Chae JI and Shim JH: The HDAC inhibitor, panobinostat, induces apoptosis by suppressing the expresssion of specificity protein 1 in oral squamous cell carcinoma. Int J Mol Med. 32:860–866. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhu P, Martin E, Mengwasser J, Schlag P, Janssen KP and Göttlicher M: Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis. Cancer Cell. 5:455–463. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Barneda-Zahonero B and Parra M: Histone deacetylases and cancer. Mol Oncol. 6:579–589. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Garcia-Guerrero E, Götz R, Doose S, Sauer M, Rodríguez-Gil A, Nerreter T, Kortüm KM, Pérez-Simón JA, Einsele H, Hudecek M and Danhof S: Upregulation of CD38 expression on multiple myeloma cells by novel HDAC6 inhibitors is a class effect and augments the efficacy of daratumumab. Leukemia. 35:201–214. 2021. View Article : Google Scholar :
|
|
18
|
Zhou Y, Liu X, Xue J, Liu L, Liang T, Li W, Yang X, Hou X and Fang H: Discovery of peptide boronate derivatives as histone deacetylase and proteasome dual inhibitors for overcoming bortezomib resistance of multiple myeloma. J Med Chem. 63:4701–4715. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sun X, Xie Y, Sun X, Yao Y, Li H, Li Z, Yao R and Xu K: The selective HDAC6 inhibitor nexturastat A induces apoptosis, overcomes drug resistance and inhibits tumor growth in multiple myeloma. Biosci Rep. 39:BSR201819162019. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Mithraprabhu S, Kalff A, Chow A, Khong T and Spencer A: Dysregulated class I histone deacetylases are indicators of poor prognosis in multiple myeloma. Epigenetics. 9:1511–1520. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Alanazi F, Kwa FAA, Burchall G and Jackson DE: New generation drugs for treatment of multiple myeloma. Drug Discov Today. 25:367–379. 2020. View Article : Google Scholar
|
|
22
|
Hadley M, Noonepalle S, Banik D and Villagra A: Functional analysis of HDACs in tumorigenesis. Methods Mol Biol. 1983:279–307. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chen Y, Zhao H, Li H, Feng X, Tang H, Qiu C, Zhang J and Fu B: LINC01234/MicroRNA-31-5p/MAGEA3 axis mediates the proliferation and chemoresistance of hepatocellular carcinoma cells. Mol Ther Nucleic Acids. 19:168–178. 2020. View Article : Google Scholar
|
|
24
|
Furuyama T, Nakazawa T, Nakano I and Mori N: Identification of the differential distribution patterns of mRNAs and consensus binding sequences for mouse DAF-16 homologues. Biochem J. 349:629–634. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhao Y, Liu Y, Lin L, Huang Q, He W, Zhang S, Dong S, Wen Z, Rao J, Liao W and Shi M: The lncRNA MACC1-AS1 promotes gastric cancer cell metabolic plasticity via AMPK/Lin28 mediated mRNA stability of MACC1. Mol Cancer. 17:692018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Brabletz T, Kalluri R, Nieto MA and Weinberg RA: EMT in cancer. Nat Rev Cancer. 18:128–134. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chaffer CL, San Juan BP, Lim E and Weinberg RA: EMT, cell plasticity and metastasis. Cancer Metastasis Rev. 35:645–654. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Quinn JJ and Chang HY: Unique features of long non-coding RNA biogenesis and function. Nat Rev Genet. 17:47–62. 2016. View Article : Google Scholar
|
|
29
|
Yao RW, Wang Y and Chen LL: Cellular functions of long noncoding RNAs. Nat Cell Biol. 21:542–551. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Pu Y, Dong Z, Xia Y, Zhang M, Song J, Han J and Liu H: LncRNA NONHSAT113026 represses renal cell carcinoma tumorigenesis through interacting with NF-κB/p50 and SLUG. Biomed Pharmacother. 118:1093822019. View Article : Google Scholar
|
|
31
|
Al Emran A, Marzese DM, Menon DR, Stark MS, Torrano J, Hammerlindl H, Zhang G, Brafford P, Salomon MP, Nelson N, et al: Distinct histone modifications denote early stress-induced drug tolerance in cancer. Oncotarget. 9:8206–8222. 2017. View Article : Google Scholar
|
|
32
|
Yeon M, Kim Y, Jung HS and Jeoung D: Histone deacetylase inhibitors to overcome resistance to targeted and immuno therapy in metastatic melanoma. Front Cell Dev Biol. 8:4862020. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Krumm A, Barckhausen C, Kücük P, Tomaszowski KH, Loquai C, Fahrer J, Krämer OH, Kaina B and Roos WP: Enhanced histone deacetylase activity in malignant melanoma provokes RAD51 and FANCD2-triggered drug resistance. Cancer Res. 76:3067–3077. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Gameiro SR, Malamas AS, Tsang KY, Ferrone S and Hodge JW: Inhibitors of histone deacetylase 1 reverse the immune evasion phenotype to enhance T-cell mediated lysis of prostate and breast carcinoma cells. Oncotarget. 7:7390–7402. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Tang Z, Ding S, Huang H, Luo P, Qing B, Zhang S and Tang R: HDAC1 triggers the proliferation and migration of breast cancer cells via upregulation of interleukin-8. Biol Chem. 398:1347–1356. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Hegedüs L, Padányi R, Molnár J, Pászty K, Varga K, Kenessey I, Sárközy E, Wolf M, Grusch M, Hegyi Z, et al: Histone deacetylase inhibitor treatment increases the expression of the plasma membrane Ca2+ pump PMCA4b and inhibits the migration of melanoma cells independent of ERK. Front Oncol. 7:952017. View Article : Google Scholar
|
|
37
|
Wang Y, Shi J, Chai K, Ying X and Zhou BP: The role of snail in EMT and tumorigenesis. Curr Cancer Drug Targets. 13:963–972. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Ye X, Brabletz T, Kang Y, Longmore GD, Nieto MA, Stanger BZ, Yang J and Weinberg RA: Upholding a role for EMT in breast cancer metastasis. Nature. 547:E1–E3. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Wang Z and Liu C: MiR-153 regulates metastases of gastric cancer through Snail. Tumor Biol. 37:15509–15515. 2016. View Article : Google Scholar
|
|
40
|
Shirley SH, Greene VR, Duncan LM, Torres Cabala CA, Grimm EA and Kusewitt DF: Slug expression during melanoma progression. Am J Pathol. 180:2479–2489. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Arienti C, Tesei A, Carloni S, Ulivi P, Romeo A, Ghigi G, Menghi E, Sarnelli A, Parisi E, Silvestrini R and Zoli W: SLUG silencing increases radiosensitivity of melanoma cells in vitro. Cell Oncol (Dordr). 36:131–139. 2013. View Article : Google Scholar
|
|
42
|
Liu H, Chen P, Jiang C, Han J, Zhao B, Ma Y and Mardan M: Screening for the key lncRNA targets associated with metastasis of renal clear cell carcinoma. Medicine (Baltimore). 95:e25072016. View Article : Google Scholar
|
|
43
|
Lin CW, Wang LK, Wang SP, Chang YL, Wu YY, Chen HY, Hsiao TH, Lai WY, Lu HH, Chang YH, et al: Daxx inhibits hypoxia-induced lung cancer cell metastasis by suppressing the HIF-1α/HDAC1/Slug axis. Nat Commun. 7:138672016. View Article : Google Scholar
|
